Articles related to LYMPHOMA

More good news for zanubrutinib, which received accelerated approval in November 2019 in the US for the treatment of mantle cell lymphoma (MCL) in adult patients who have undergone at least one prior therapy. The supplemental new drug application (sNDA) was submitted by the drug’s manufacturer, BeiGene, based on data from the global phase III ASPEN trial.

This fascinating case of a 61-year-old male in the UK is the only report so far regarding COVID-19 induced cancer remission. Ridden with stage 3 Hodgkin lymphoma, the COVID-19 infected patient was hospitalized for 11 days but did not receive any cancer treatments. Four months later, PET-CT scans show the lymphoma largely gone. How did this happen and what are the implications for new treatments?

How can oncologists successfully implement precision medicine strategies in diffuse large B-cell lymphoma (DLBCL)? In this review, the authors describe the recently proposed genomic categories of DLBCL and their potential use for personalized treatment, as well as the significant challenges they will present.